Skip to content

Press Release · Press Releases

Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results

Issued by PR Newswire

Image: PR Newswire

Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 Billion INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 Billion SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third...

This press release summary is reproduced from the issuer's public feed.

Read the full release at PR Newswire

Original publisher: PR Newswire

Spotted an error? Request a correction · Corrections Policy

Related stories

Press Release

MAA Announces Pricing of Senior Unsecured Notes Offering

GERMANTOWN, Tenn., Nov. 2, 2026 /PRNewswire/ -- Mid-America Apartment Communities, Inc., ("MAA") (NYSE: MAA) today announced that its operating partnership, Mid-America Apartments, L.P. ("MAALP"), priced a $350,000,000 offering of MAALP's 5.350% senior unsecured notes due December 15,...

PR Newswire ·